Sirolimus has “a much wider” safety window and shows fewer local effects than paclitaxel


Paclitaxel kills the cells in the artery wall; sirolimus simply stuns them. So says Peter Gaines (Sheffield, UK) at VLF 2019 while commenting on the modes of action of these two agents that have been used in drug-coated devices in both the coronary and peripheral vessels. Sirolimus is likely to have fewer systemic problems [than paclitaxel] and is much less likely to have local toxic effects on the arteries, he says.


Please enter your comment!
Please enter your name here